Metrics as of 10/17/2026, 06:06 AM (Berlin time), refresh in progress.
ABVC BioPharma Stock
ABVC BioPharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Uttam Yashwant Patil
- Employees
- 18
- Market cap
- $25 M
- IPO
- 10/11/2004
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is…
ABVC BioPharma stock: price history
1D
-1.6%
1W
-8.2%
1M
-15.0%
6M
-30.5%
YTD
-56.9%
1Y
-68.6%
2Y
+64.5%
5Y
-96.6%
10Y
-99.7%
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~73% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about ABVC BioPharma
Analyst assessment of ABVC BioPharma
0
STRONG BUY
0
BUY
1
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Hold
As of: 16/11/2022
ABVC BioPharma stock metrics
P/E
-3.11
P/B
2.33
EV/EBITDA
-3.39
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.0%
FLOAT SHARES
21,095,690
AVG. DAILY VOLUME (30D)
115,046
Dividends & Stock splits
Comparable stocks
Frequently asked questions about ABVC BioPharma stock
What does ABVC BioPharma do?
ABVC BioPharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Uttam Yashwant Patil, the company employs around 18 people.
The IPO was on 10/11/2004; the stock trades on NASDAQ under the ticker ABVC.
What do analysts say about ABVC BioPharma stock?
1 analysts rate the stock, the consensus is Hold (as of 16/11/2022).
This is an external assessment, not a statement by Market Jury.
When does ABVC BioPharma report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly -73% stronger than usual.
Does ABVC BioPharma pay a dividend?
No, ABVC BioPharma currently does not pay a dividend.
Which stocks are comparable to ABVC BioPharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ABVC BioPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess ABVC BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.